Drug Profile
Research programme: GLP-1 analogue depot implant - Matregen
Alternative Names: GLP-1-Depot-X™ implantLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Matregen Corp
- Class
- Mechanism of Action Glucagon-like peptide 1 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in Canada (SC, Implant)
- 13 Apr 2007 The technology is available for licensing (http://www.matregen.com)
- 12 Apr 2007 Preclinical trials in Type-2 diabetes mellitus in Canada (SC)